- Investment in the Biotechnology Center is a double-digit million-euro sum.
- The center is scheduled to be operational in 2024.
- WACKER aims for €1 billion in sales from BIOSOLUTIONS by 2030.
- Research will focus on biopharmaceuticals and fermentation-based food ingredients.

Investment and Timeline
The WACKER Group is investing a double-digit million-euro sum in a new Biotechnology Center in Munich, set to be operational by 2024. This initiative aims to enhance the company's biotechnology research capabilities.
Strategic Goals
WACKER plans to significantly increase its investment in biotechnology, with a target of contributing around €1 billion to Group sales by 2030. The strategy includes expanding the product portfolio through innovation, partnerships, and acquisitions.
Research Focus
The Biotechnology Center will focus on the manufacturing processes of biopharmaceuticals, particularly advanced medicines, and the fermentation-based production of food ingredients and supplements. The consolidation of R&D activities under one roof is expected to improve research efficiency.
Facility Details
Located at the Consortium für elektrochemische Industrie, WACKER's corporate research facility, the center will cover approximately 2,000 square meters over three floors. It will accommodate around 90 employees, alleviating current capacity constraints.
Collaboration and Development
The center will also provide space for staff from the BIOSOLUTIONS division and project groups. It aims to bridge the gap between R&D and practical application, working with customers and development partners to evaluate market demand, partnerships, and cost-benefit ratios for new projects.